Affiliation:
1. Department of Surgery, Division of Otolaryngology–Head & Neck Surgery, University of Connecticut School of Medicine, Farmington, Connecticut
Abstract
Hypothesis
Cyclodextrin (CDX)-induced serum prestin burst is not dependent on outer hair cell (OHC) loss.
Background
Serum prestin has been proposed as a biomarker for ototoxicity. We recently used an automated Western approach to quantify serum prestin changes in a newly introduced model of CDX ototoxicity. To gain insights into prestin as a biomarker, here we further characterize serum prestin in the CDX model.
Methods
Guinea pigs were treated with 750, 3,000, or 4,000 mg/kg CDX, and serum samples were obtained through up to 15 weeks after exposure. Serum prestin levels were quantified using automated Western, and hair cell counts were obtained.
Results
All three doses induced an N-glycosylated ~134-kDa prestin burst; however, only the 3,000 and 4,000 mg/kg resulted in robust OHC loss. Prestin levels returned to baseline where they remained up to 15 weeks in the absence of OHCs.
Conclusion
The ~134-kDa prestin burst induced after CDX administration is N-glycosylated, representing a posttranslational modification of prestin. Serum prestin seems to be a promising biomarker when using therapeutics with ototoxic properties because it is not dependent on OHC loss as a necessary event, thus affording the opportunity for early detection and intervention.
Publisher
Ovid Technologies (Wolters Kluwer Health)